GRACILE syndrome
MONDO:0011308GRACILE syndrome is an inherited lethal mitochondrial disorder characterized by fetal growth restriction (GR), aminoaciduria (A), cholestasis (C), iron overload (I), lactacidosis (L), and early death (E).
Also known as: Fellman disease, Growth restriction-aminoaciduria-cholestasis-iron overload-lactic acidosis-early death syndrome, gracile syndrome, FLNMS, Fellman syndrome, Finnish lactic acidosis with hepatic hemosiderosis, Finnish lethal neonatal metabolic syndrome, Growth retardation, amino aciduria, cholestasis, iron overload, lactic acidosis, and early death
13 clinical trials for this condition and its sub-types, 0 tagged with GRACILE syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC